Evidence map›Paper›PMID 36278672›Full record

ReviewVision (Basel, Switzerland)2022

"Vision Loss" and COVID-19 Infection: A Systematic Review and Meta-Analysis.

Matteo Ripa, Lorenzo Motta, Chiara Schipa, Stanislao Rizzo, Liliana Sollazzi, Paola Aceto

Abstract readReview
In one paragraph

Review in Vision (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The effect of COVID-19 on visual outcome and dry eye after SMILE.Advances in ophthalmology practice and research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matteo RipaOphthalmology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0001-7968-1336
Lorenzo MottaDepartment of Ophthalmology, William Harvey Hospital, East Kent Hospitals University NHS Foundation Trust, Ashford TN24 0LZ, UK.
Chiara SchipaCatholic University "Sacro Cuore", 00168 Rome, Italy.ORCID 0000-0003-3856-5616
Stanislao RizzoOphthalmology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Liliana SollazziCatholic University "Sacro Cuore", 00168 Rome, Italy.
Paola AcetoCatholic University "Sacro Cuore", 00168 Rome, Italy.ORCID 0000-0002-0228-0603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVisual impairment in terms of reduced visual acuity and "visual loss" has been reported as an atypical symptom in patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This systematic review and meta-analysis aims to assess the cumulative incidence of "visual loss" during coronavirus disease 2019 (COVID-19) and review the current evidence regarding "visual loss" caused by SARS-CoV-2 infection.

methodsWe performed a systematic review and meta-analysis of studies following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We systematically searched the PubMed, Embase, and Scopus databases for relevant studies published that clearly described "vision loss" and SARS-CoV-2 infection. All studies reporting concomitant "vision loss" and laboratory-confirmed SARS-CoV-2 infection were included. Meta-analyses were conducted using the measurement of risk and a 95% confidence interval for each study.

resultsOur search identified 1143 manuscripts published in the English language. After study screening, twenty-nine articles were selected: two cross-sectional studies, twenty-four case reports, and three case series. A random-effect meta-analysis demonstrated that the pooled "visual loss" cumulative incidence in COVID-19 patients was 0.16 (95% CI 0.12-0.21). The quality rating of the cross-sectional studies averaged four out of the maximum score on the Newcastle-Ottawa scale.

conclusionsCOVID-19 infection might cause "visual loss". Even if the current evidence is limited, ophthalmological assessment should be promptly provided to all patients experiencing visual impairment symptoms during SARS-CoV-2 infection.

Indexed as

COVID-19poor visionvisual impairment

Identifiers

PMID36278672
PMCPMC9589937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.